NBIX241115P210000
- 0.00
- 0.000.00%
Neurocrine Biosciences Newsroom
Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $170
Evercore Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $175
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $136 to $192
Neurocrine Biosciences Analyst Ratings
Needham Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating
Needham Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating
Mizuho Securities Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating
Oppenheimer Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $192
Neurocrine Biosciences Analyst Ratings
BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $114
Barclays Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $160
Piper Sandler Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $159
Jefferies Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $169
Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $170
Neurocrine (NBIX) Gets a Buy From Jefferies
Raymond James Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $155
Neurocrine Biosciences Analyst Ratings
Raymond James Reinstates Outperform on Neurocrine Biosciences, Announces $155 Price Target
RBC Capital Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Cuts Target Price to $133
Barclays Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $160